pg/ml and LVH will be enrolled in the study. 23 The primary study endpoint is change from baseline to 12 months in left ventricular mass index (LVMI; g/m 2 ) measured 24 by cardiac magnetic resonance imaging. Sample size calculations showed that 62 randomized patients will be 25 necessary to detect a difference in LVMI of at least 20 g/m 2 between the two groups at 12 months. Due to the strong 26 association of volume overload and LVH, randomization will be stratified by residual kidney function, and regular body 27 composition monitoring will be performed to control the volume status of patients. 28 Study medication will be administered intravenously by the dialysis nurses after every hemodialysis session, thus 29 omitting adherence issues. 30 Secondary study endpoints are cardiac parameters measured by echocardiography, biomarker concentrations of bone 31 metabolism (FGF23, vitamin D, parathyroid hormone, calcium, phosphate, s-Klotho), cardiac markers (pro-brain natriuretic 32 peptide, pre-and postdialysis troponin T) and metabolites of the renin-angiotensin-aldosterone cascade (angiotensin I 33 (Ang I), Ang II, Ang-(1-7), Ang-(1-5), Ang-(1-9), and aldosterone). 34 Discussion: The causal inference and pathophysiology of LVH regression by FGF23 reduction using calcimimetic 35 treatment has not yet been shown. This intervention study has the potential to discover a new strategy for the 36 treatment of cardiac hypertrophy and fibrosis in patients on maintenance hemodialysis. It might be speculated that 37 successful treatment of cardiac morphology will also reduce the risk of cardiac death in this population. 38 Trial registration: European Clinical Trials Database, EudraCT number 2017-000222-35; ClinicalTrials.gov, NCT03182699. 39 148 who qualify for the study will be randomized at a 1:1 149 ratio to the ETL group or the ALFA group. 150 Randomization will be performed by a computer algo-151 rithm (www.meduniwien.ac.at/randomizer/web) and 152 will be stratified by residual kidney function (< 500 ml 153 versus ≥ 500 ml urine per day) and the center where 154 patients are recruited (Medical University of Vienna 155 versus Vienna Dialysis Center). To ensure that com-156 parison groups will be of approximately the same size 157 and balanced in each center, a block randomization 158 (block size of 4) will be used. 159 Treatment phase 160 The treatment phase starts with a dose-titration phase of 161 16 weeks. Subjects will be considered for dose titration 162 of the investigational product every 4 weeks. Dose ad-163 justment will be based upon PTH values, serum electro-164 lytes and safety assessment. Study visits will take place in 165 2-week intervals during the first 10 weeks of treatment 166 followed by study visits every 4 weeks. The duration of 167 the treatment phase is 12 months.
168

Study endpoints 169
The primary endpoint is the change in LVMI (quantified 170 in grams per meter squared) from baseline to 12 months 171 between the ETL and ALFA groups as assessed by The cMRI will be analyzed by one radiologist blinded to 198 the treatment allocation. Noncontrast cMRI will be car-199 ried out using a 1.5-Tesla MRI scanner (Siemens Avanto For the detection of myocardial fibrosis, fat-suppressed 218 T2-weighted edema-sensitive imaging will be performed. 219 Noncontrast T1 mapping will be performed to detect 220 diffuse fibrotic processes (T1 time is measured in milli-221 seconds for global, septal and nonseptal times). The na-222 tive myocardial T1 relaxation is a surrogate of 223 myocardial fibrosis [43] . In hemodialysis patients the in-224 terventricular septum appears to be particularly prone to 225 the development of fibrosis [44] . 226 Strain echocardiography 227 Echocardiography for the evaluation of LVH will take 228 place during screening as well as at the end of the treat-229 ment phase. Doppler imaging or two-dimensional 230 speckle tracking echocardiography is used to measure 231 strain and strain rate. With these techniques subclinical 232 heart disease in fibrotic processes can be detected, with 233 the predominant planes of strain that are initially af-234 fected mirroring the histological location of early fibrosis 235 [45, 46] . Global longitudinal strain is measured as per-236 cent and correlates well with myocardial fibrosis [47] . 237 The physician performing the examination will be 238 blinded to the patient's treatment assignment.
239 Body composition monitoring 240 BCM will be performed during screening and will be re-241 peated at 2-month intervals. BCM measurements are 242 based on bioimpedance spectroscopy. The measure-243 ments are fed into a model to measure overhydration of Additionally, an 272 RAAS fingerprint will be conducted at the start and at 273 the end of the treatment phase [25, 28, 29, 50]. The 274 RAAS fingerprint is a mass spectrometry-based quantifi-275 cation of angiotensin metabolites, which will be performed 276 by a resident diagnostic service provider (Attoquant Diag-277 nostics). Serum samples will be used to measure the fol-278 lowing parameters: Ang I, Ang II, Ang-(1-7), Ang-(1-5), 279 Ang-(1-9) and aldosterone.
280
Intact PTH, calcium and phosphate will be analyzed in 281 serum samples using the Cobas assay (Roche; reference 282 ranges: PTH 15-65 pg/ml, calcium 2.15-2.55 mmol/l 283 and phosphate 0.81-1.45 mmol/l). Vitamin D will be 284 measured using serum samples chemiluminescent immu-285 noassays (DiaSorin; reference ranges: 1,25-(OH) 2 D 19.9-286 79.3 pg/ml and 25(OH)D 75-250 nmol/l). Ionized calcium 287 will be measured during every dialysis session (using blood 288 gas analysis (ABL 800 Flex, Drott)). Intact FGF23 will be 289 analyzed in plasma samples using chemiluminescent im-290 munoassays (DiaSorin; reference range: 23.2-95.4 pg/ml). 291 TnT and proBNP will be measured from serum samples 292 using Cobas electrochemiluminescence immunoassays should be between 2.5 mg and 15 mg three times a week.
310
The starting dose is 5 mg three times a week. To achieve 311 a target value of PTH (100-300 pg/ml), the dosage will 312 be adapted every 4 weeks in steps of 2.5 or 5 mg during 313 the titration phase. Serum calcium will be measured at 
316
ALFA is an analogue of vitamin D3. ALFA can de-317 crease PTH levels by ≥ 30% and increase FGF23 levels 318 threefold [53]. In general, ALFA is a safe and well-319 tolerated established treatment for sHPT.
320
The starting dose is 1 μg, administered as an intraven-321 ous bolus three times a week at the end of hemodialysis. 322 ALFA dosage should be at least 0.5 μg three times a 323 week with no maximal dose. Titration will be performed 324 in 0.5-to 1-μg steps at 4-week intervals, depending on 325 PTH values and serum calcium and phosphate levels. 326 The target value of PTH is equivalent to the ETL group. 327 Serum calcium corrected for serum albumin should be 328 no higher than 2.55 mmol/l and serum phosphate levels 329 should be below 2.5 mmol/l.
330
The goal is to achieve a similar reduction in PTH 331 in both study groups while FGF23 is elevated in the 332 ALFA arm and suppressed in the ETL arm in order 333 to analyze the causality of FGF23 reduction on LVH 334 and fibrosis. 335 However, it is likely that the levels of PTH will vary, 336 simply due to the different pharmacodynamics of the 337 two drugs. Even though the dose of the study medica-338 tion can be changed during the drug titration period as 339 well as later on when necessary in order to reach target 340 PTH levels, these adaptations are often limited by serum 341 calcium and phosphate levels. 342 Other HPT treatments 343 Cinacalcet treatment as well as oral and intravenous 344 vitamin D therapy will be discontinued during the wash-345 out phase of 4 weeks. Phosphate binder therapy can be 346 continued and will be adapted depending on serum elec-347 trolytes during the treatment phase. There are no re-348 strictions on calcium supplements, the dialysate calcium 349 concentration, or the type or dose of phosphate binders 350 prescribed. Participants randomized to ETL can receive 351 additional vitamin D analogs as a rescue therapy only 352 when the investigator thinks that it is necessary to pro-353 tect participant safety. The study monitor will contact and visit the investigator 368 regularly and will be allowed, on request, to have access 369 to all source documents needed to verify the entries in 370 the electronic documentation and other study-related 371 documents provided that subject confidentiality is main-372 tained in agreement with local regulations. It will be the 373 monitor's responsibility to inspect the electronic case re-374 port forms at regular intervals throughout the study to 375 verify the adherence to the study protocol and the com- The diagnosis of LVH prior to enrollment in the study 523 poses a certain difficulty regarding the accuracy of echo-524 cardiographic quantification of LVH. However, since 525 each patient serves as his or her own control, the pro-526 gression of left ventricular mass can be demonstrated 527 during the course of the 12 months of treatment.
528
This trial is designed to visualize changes in cardiac 529 muscle mass and fibrosis as a result of modified FGF23 530 levels which might be causal to the improved cardiovas-531 cular outcomes under lower FGF23 described in the 532 EVOLVE study. If our study proves that ETL can effect-533 ively ameliorate LVH and cardiac fibrosis trough a sup-534 pression of FGF23, it may potentially provide a valuable 535 basis for a pharmaceutical target aiming at reducing the 536 high rate of cardiac death in patients under maintenance 537 hemodialysis.
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